On June 10, 2024, Julie Mchugh, Director at Ironwood Pharmaceuticals Inc (IRWD, Financial), executed a sale of 22,766 shares of the company. According to the SEC Filing, the transaction occurred at a stock price of $6.29 per share. Following this transaction, the insider now owns 139,528 shares of Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is engaged in the development and commercialization of human therapeutic products. The company primarily focuses on medicines targeting gastrointestinal diseases but is also involved in the research and development of treatments for other conditions.
Over the past year, the insider transaction history at Ironwood Pharmaceuticals Inc shows a pattern of more sales than purchases among insiders. There have been 15 insider sales and only 3 insider buys during this period.
Currently, Ironwood Pharmaceuticals Inc has a market cap of $1.014 billion. The stock's valuation metrics, such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are calculated based on historical trading multiples, adjusted for the company's past performance and expected future business outcomes.
The stock's current price of $6.29 compares to a GF Value of $12.04, indicating a price-to-GF-Value ratio of 0.52. This suggests that Ironwood Pharmaceuticals Inc is currently seen as a Possible Value Trap, and potential investors should think twice before investing.
This sale by the insider might be of interest to current and potential investors, as it provides insight into the insider's perspective on the stock's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
